Find Paid Research Studies in Aurora, Illinois

Condition:   Peripheral Arterial Disease
Interventions:   Drug: edoxaban;   Drug: Clopidogrel;   Drug: Aspirin
Sponsors:   Daiichi Sankyo Inc.;   Daiichi Sankyo Inc.;   UMC Utrecht
Recruiting - verified March 2013

Condition:   Atrial Fibrillation
Intervention:   Other: Patients with Atrial Fibrillation
Sponsors:   Janssen Scientific Affairs, LLC;   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
Recruiting - verified April 2013

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   The Cleveland Clinic
Recruiting - verified May 2013

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonist (VKA)
Sponsors:   Bayer;   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2013

Condition:   Hypercholesterolemia
Interventions:   Drug: PBO;   Drug: 200mg PF-04950615 (RN316);   Drug: 300mg PF-04950615 (RN316);   Drug: PBO;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: PF-04950615
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2013

Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: pharmacological study;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified April 2013

Conditions:   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: sunitinib malate;   Other: placebo;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Condition:   Endometrial Cancer
Interventions:   Drug: cisplatin;   Radiation: brachytherapy;   Radiation: external beam radiation therapy
Sponsors:   Gynecologic Oncology Group;   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions:   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified May 2013

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   Pfizer;   The Cleveland Clinic
Recruiting - verified May 2013

Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions:   Drug: cisplatin;   Drug: tirapazamine
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI);   NCIC Clinical Trials Group
Recruiting - verified May 2013